跳至主要内容
临床试验/CTRI/2024/02/062617
CTRI/2024/02/062617尚未招募4 期

To study the efficacy and safety of Aripiprazole vs Naltrexone in managing antipsychotic induced weight gain- A randomized controlled trial - NI

Madhurima Dhar0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients who are on antipsychotic treatment for a duration of at least 3 months
  • 2. who have gained weight by 5 % in the last 3 months.
  • 3. All patients irrespective of gender and diagnosis
  • 4. Female participants of childbearing potential to have a negative pregnancy test at screening and pre-dose, and willing to practice adequate methods of contraception during the study

排除标准

  • 1.Those who have hypersensitivity to aripiprazole or naltrexone
  • 2. Those who develop side effects that are bothersome including Fulminant hepatitis or extreme hypersensitivity reactions.
  • 3. Those with uncontrolled thyroid disorder or uncontrolled diabetes mellitus.
  • 4. Among females, those who are pregnant or lactating
  • 5. Current alcohol or substance abuse or dependence
  • 6. Those who used any medication for weight loss within the preceding month prior to study entry.
  • 7. Patients who do not provide valid informed consent

研究者

发起方
Madhurima Dhar

相似试验